AMI Asset Management Corp Sells 1,309 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

AMI Asset Management Corp trimmed its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 3.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,151 shares of the biopharmaceutical company’s stock after selling 1,309 shares during the quarter. AMI Asset Management Corp’s holdings in Halozyme Therapeutics were worth $2,307,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Smartleaf Asset Management LLC increased its stake in shares of Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 197 shares during the last quarter. Bessemer Group Inc. grew its stake in Halozyme Therapeutics by 62.9% in the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 207 shares during the last quarter. Parallel Advisors LLC grew its stake in Halozyme Therapeutics by 12.5% in the 1st quarter. Parallel Advisors LLC now owns 1,875 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 208 shares during the last quarter. Baird Financial Group Inc. grew its stake in Halozyme Therapeutics by 2.0% in the 4th quarter. Baird Financial Group Inc. now owns 11,119 shares of the biopharmaceutical company’s stock valued at $532,000 after buying an additional 221 shares during the last quarter. Finally, Portside Wealth Group LLC grew its stake in Halozyme Therapeutics by 2.4% in the 1st quarter. Portside Wealth Group LLC now owns 9,317 shares of the biopharmaceutical company’s stock valued at $595,000 after buying an additional 222 shares during the last quarter. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Stock Down 2.9%

Shares of NASDAQ HALO opened at $52.32 on Thursday. The firm has a market cap of $6.45 billion, a PE ratio of 13.91, a P/E/G ratio of 0.36 and a beta of 1.19. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $70.51. The company’s fifty day simple moving average is $56.28 and its 200 day simple moving average is $56.34. The company has a quick ratio of 7.30, a current ratio of 8.39 and a debt-to-equity ratio of 3.13.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.13. The business had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. Halozyme Therapeutics’s revenue was up 35.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.79 earnings per share. As a group, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $53.73, for a total value of $1,074,600.00. Following the transaction, the chief executive officer now directly owns 733,719 shares of the company’s stock, valued at approximately $39,422,721.87. This trade represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffrey William Henderson sold 4,497 shares of the firm’s stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $60.37, for a total transaction of $271,483.89. Following the transaction, the director now directly owns 28,611 shares in the company, valued at $1,727,246.07. The trade was a 13.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 45,000 shares of company stock valued at $2,437,501. Corporate insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Benchmark downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 7th. Leerink Partners downgraded shares of Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 price objective for the company. in a report on Tuesday, May 13th. Leerink Partnrs downgraded shares of Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 13th. Wells Fargo & Company boosted their price objective on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an “equal weight” rating in a report on Wednesday, May 7th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a “neutral” rating in a report on Monday, April 21st. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $61.90.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.